In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

This was the stock's second consecutive day of gains.

Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

Merck held talks over a potential $3 billion acquisition of MoonLake Immunotherapeutics, as it seeks to replenish its drug pipeline ...

Shares of small-biotech MoonLake Immunotherapeutics MLTX rose 18% yesterday following a report issued by the Financial Times ...

The USPTO’s Patent Trial and Appeal Board instituted Merck’s (MRK) patent grant review against Halozyme’s (HALO) MDASE patents after Merck filed a Petition requesting post-grant review of claims 1-21 ...

Merck (MRK) ended the recent trading session at $78.27, demonstrating a +1.46% swing from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.01% for the ...

Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights.

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

China has recently approved the nation's first homegrown nine-valent human papillomavirus vaccine (HPV), said the domestic ...

As a result of the decision, Shilpa will not be eligible to receive FDA approval for its lenvatinib mesylate generic until February 2036.